Vaxart provides update on proxy voting

KUALA LUMPUR, July 28 (Bernama) -- Clinical-stage biotechnology company Vaxart Inc urged its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so and encouraged them to vote yes on all Proxy Proposals, including Proxy Proposal #2.

Proposal #2 is an amendment to the Company’s Restated Certificate of Incorporation to increase the authorised number of shares of its common stock to 250 million shares.

“Proposal #2 is important for shareholders and for the company, because it would enable us to continue to work to unlock and create value by investing in the business so that we can progress our programmes,” said Vaxart’s Chief Executive Officer Andrei Floroiu in a statement.

“It would also allow us to maintain a strong balance sheet and remain in a strong competitive position, and it would enable us to continue to attract and retain key talent. We strongly urge shareholders to vote before the Aug 3, 2022, deadline.”

Both leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis, recommend that shareholders support Proposal #2.

Vaxart’s 2022 Annual Meeting of Stockholders was adjourned to Aug 4.

-- BERNAMA